[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f65-g5LTUgHIk8dGZIHhGe2pKpxnfW0g-O4HGxk3yxcs":3,"$f9kyDJs6otbFaCZ0aLYgXUBLx01jtVPJXW8fgC7EorUM":8,"$fni95NOeQsf_Hs0K0cw-Fo8agmbZI59BKgcrU3wk7o0Q":55,"$fzQ4yQQTdWxjNtW4J7RdV4GiDS5tfv8mmBvEarYa2UIw":59},{"code":4,"msg":5,"message":6,"data":6,"success":7},401,"认证失败，无法访问系统资源",null,false,{"code":9,"msg":10,"message":6,"data":11,"success":54},200,"操作成功",{"id":12,"specialistId":13,"specialistAssistants":14,"profilePhoto":15,"specialistName":16,"hospital":17,"department":18,"postsTitle":19,"materialTotal":20,"videoTotal":21,"isConcern":7,"title":22,"coverVertical":23,"coverAcross":24,"content":25,"description":26,"views":27,"likes":21,"isThumbsUp":7,"isCollection":7,"collections":21,"createTime":28,"seoTitle":22,"seoKeywords":29,"seoDescription":30,"shelvesTime":31,"version":32,"menus":33,"menuId":35,"type":42,"quality":53,"commentCount":21,"isComment":42},71861,870289,[],"https://cdn.haohuanjiao.com/learnMaterial/ystApp//1dd0wCFxaNJ5ORyGzM4AjBTI4T648wCX.png","张荣娟","隆尧县山口镇卫生院（隆尧县第十三医院）","妇科","住院医师",6,0,"🎯 HER2靶向常用药用药细节全解——安全与实用并重","","https://ystcdn.venuertc.com/venue/AI/ccbc8643-6db4-4776-bbfe-5f7bccbcf779.jpg","\u003Cdiv class=\"medher2-container\">\n  \u003Ch1 id=\"material_title\" class=\"medher2-title\">\n    🎯 HER2靶向常用药用药细节全解——安全与实用并重\n  \u003C/h1>\n  \u003Cdiv class=\"medher2-intro\">\n    日常生活中提到靶向药物，很多人第一反应就是“副作用大、用药复杂”。其实，像曲妥珠单抗、帕妥珠单抗这样的HER2靶向药，已经是现代治疗领域的重要工具。它们以独特机制介入治疗，但要用得好，必须掌握一些关键细节。本文将聚焦乳腺癌HER2阳性常用药的服用方法、剂型挑选、相互作用、防风险用药等要点，全程只讲药品本身，让你一目了然正确且安全的用药策略。\n  \u003C/div>\n\n  \u003C!-- 01 药物组成与剂型 -->\n  \u003Csection class=\"medher2-section medher2-bg1\">\n    \u003Ch2 class=\"medher2-subtitle\">01 药品的成分与剂型选择 🧬\u003C/h2>\n    \u003Cdiv class=\"medher2-content\">\n      \u003Cul>\n        \u003Cli>\n          \u003Cstrong>常用HER2靶向药：\u003C/strong>曲妥珠单抗、帕妥珠单抗、聚乙二醇化粒细胞刺激因子、双环醇片等。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>剂型分类：\u003C/strong>曲妥珠单抗和帕妥珠单抗多为注射用冻干粉剂，通过静脉输注或皮下注射给药。聚乙二醇化粒细胞刺激因子为皮下注射制剂。双环醇片为口服制剂。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>注射剂特别注意：\u003C/strong>部分制剂需要稀释后静脉缓慢滴注，不可快速推注。皮下注射部位定期更换，避免局部刺激。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>片剂用药方法：\u003C/strong>口服片剂需用足量温水送服，避免嚼碎。\n        \u003C/li>\n      \u003C/ul>\n      \u003Cdiv class=\"medher2-tip medher2-tip-middle\">\n        ✅ 正确做法：遵循说明书或专业人士指导，按剂型规范操作，每次用药前后检查外观与包装。\n      \u003C/div>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 02 药物作用机制（只讲机制，不讲用法） -->\n  \u003Csection class=\"medher2-section medher2-bg2\">\n    \u003Ch2 class=\"medher2-subtitle\">02 HER2靶向药的作用机制 🔬\u003C/h2>\n    \u003Cdiv class=\"medher2-content\">\n      \u003Cul>\n        \u003Cli>\n          \u003Cstrong>曲妥珠单抗：\u003C/strong>是一种单克隆抗体，能够特异性结合HER2受体，阻断其信号通路，减少异常细胞增殖。（Baselga et al., 2012）\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>帕妥珠单抗：\u003C/strong>同属抗HER2单克隆抗体，但作用部位不同，两者联合时能产生协同作用干扰信号传递，增强抑制效果。（Swain et al., 2013）\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>聚乙二醇化粒细胞刺激因子：\u003C/strong>刺激骨髓释放白细胞，加速粒细胞生长，帮助减轻化疗引起的粒细胞减少风险。（Smith et al., 2006）\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>双环醇片：\u003C/strong>对肝功能具有一定保护作用，改善肝细胞代谢。\n        \u003C/li>\n      \u003C/ul>\n      \u003Cdiv class=\"medher2-tip medher2-tip-light\">\n        ✅ 正确做法：了解机制有助于合理联合用药，减少不必要的重复和风险。\n      \u003C/div>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 03 药物正确用法用量（只讲方法，不讲机制） -->\n  \u003Csection class=\"medher2-section medher2-bg1\">\n    \u003Ch2 class=\"medher2-subtitle\">03 合理使用方法，剂量怎么掌握 💉\u003C/h2>\n    \u003Cdiv class=\"medher2-content\">\n      \u003Cul>\n        \u003Cli>\n          \u003Cstrong>曲妥珠单抗：\u003C/strong>典型用法为静脉注射，首剂与维持剂量有所不同，严格按照体重和说明书计算。输注初次剂量需缓慢，监测反应。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>帕妥珠单抗：\u003C/strong>也是静脉注射，起始和维持剂量严格区分，不得更换给药顺序。与曲妥珠单抗可同日，但不同管路。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>聚乙二醇化粒细胞刺激因子：\u003C/strong>以皮下注射为主，通常选择上臂、大腿或腹部。注射后观察30分钟，防过敏。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>双环醇片：\u003C/strong>建议随餐用温水整片服下，避免空腹或自作主张增减次数。\n        \u003C/li>\n      \u003C/ul>\n      \u003Cdiv class=\"medher2-tip medher2-tip-middle\">\n        ✅ 建议：每次注射须有专业人员操作，口服药应固定时间，方便记忆和督查。\n      \u003C/div>\n      \u003Cdiv class=\"medher2-case medher2-case-light\">\n        案例 👩‍⚕️：临床有患者使用帕妥珠单抗和曲妥珠单抗联合时，两药混合输注，导致输注反应加重。正确做法应分开输注通路。\n      \u003C/div>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 04 药物配伍禁忌与相互作用 -->\n  \u003Csection class=\"medher2-section medher2-bg2\">\n    \u003Ch2 class=\"medher2-subtitle\">04 同时用药，这些配伍禁忌要避开 🚦\u003C/h2>\n    \u003Cdiv class=\"medher2-content\">\n      \u003Cul>\n        \u003Cli>\n          \u003Cstrong>曲妥珠单抗/帕妥珠单抗：\u003C/strong>同类靶向药可以联合用药，但必须独立通道或分开时间给药。不可与其他免疫抑制剂（如环磷酰胺等）混溶注射。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>聚乙二醇化粒细胞刺激因子：\u003C/strong>不建议同日与化疗用药同时注射，宜于化疗24小时后单独使用。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>双环醇片：\u003C/strong>与某些肝酶诱导剂（如苯巴比妥）合用可影响效果，需酌情调整。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>注意：\u003C/strong>除说明书允许配伍外，不得自行混药或更改输注方案。\n        \u003C/li>\n      \u003C/ul>\n      \u003Cdiv class=\"medher2-tip medher2-tip-light\">\n        ✅ 正确做法：每新增一种药物都应咨询专业人士，确认有无相互作用或冲突风险。\n      \u003C/div>\n      \u003Cdiv class=\"medher2-case medher2-case-middle\">\n        案例 🧑‍⚕️：有位成年患者短时内联合多种静脉药物，导致注射部位出现肿胀。分时分管后征状改善。\n      \u003C/div>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 05 特殊人群用药须知 -->\n  \u003Csection class=\"medher2-section medher2-bg1\">\n    \u003Ch2 class=\"medher2-subtitle\">05 特殊人群用药小贴士 👨‍👩‍👧‍👦\u003C/h2>\n    \u003Cdiv class=\"medher2-content\">\n      \u003Cul>\n        \u003Cli>\n          \u003Cstrong>老年患者：\u003C/strong>肾功能、肝功能减退者建议根据监测结果调整剂量，忌自行增减用药频率。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>孕妇：\u003C/strong>部分HER2靶向药（如曲妥珠单抗、帕妥珠单抗）对胎儿风险较高，原则上禁用，需避孕措施。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>哺乳期：\u003C/strong>建议暂停哺乳，待治疗结束恢复。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>肝肾功能异常者：\u003C/strong>使用双环醇片等支持药物需密切观察实验室指标，酌情减量。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>儿童群体：\u003C/strong>部分药品未充分验证安全性，需专业儿科医生监控。\n        \u003C/li>\n      \u003C/ul>\n      \u003Cdiv class=\"medher2-tip medher2-tip-middle\">\n        ✅ 特别提醒：遇到生理特殊时期、慢性基础疾病者，每次新药启用都应做全面审核。\n      \u003C/div>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 06 常见不良反应识别与处理 -->\n  \u003Csection class=\"medher2-section medher2-bg2\">\n    \u003Ch2 class=\"medher2-subtitle\">06 不良反应怎么早识别和应对 ⚠️\u003C/h2>\n    \u003Cdiv class=\"medher2-content\">\n      \u003Cul>\n        \u003Cli>\n          \u003Cstrong>曲妥珠单抗/帕妥珠单抗：\u003C/strong>静脉给药常见输注相关反应，如发热、寒战，首次用药尤其需要观察。部分患者有心脏功能异常风险，应用期间建议定期评估心脏功能。（Baselga et al., 2012）\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>聚乙二醇化粒细胞刺激因子：\u003C/strong>主要副反应为骨痛或局部过敏，极少数可能引发过敏反应（发红、瘙痒）。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>双环醇片：\u003C/strong>消化道不适、腹泻为多见，不建议加倍服药缓解不适。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>急性反应处理：\u003C/strong>出现输注相关反应、皮疹、呼吸异常时，应立即暂停用药就医，不可自行延误处理。\n        \u003C/li>\n      \u003C/ul>\n      \u003Cdiv class=\"medher2-tip medher2-tip-expert\">\n        ✅ 正确做法：首次注射严格院内操作，口服药物如出现异常及时停药并联系专业人士。\n      \u003C/div>\n      \u003Cdiv class=\"medher2-case medher2-case-light\">\n        案例 🩺：临床患者用聚乙二醇化粒细胞刺激因子时，注射后出现皮肤瘙痒，经停药，抗过敏药处理后缓解。\n      \u003C/div>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 07 储存与过期处理要点 -->\n  \u003Csection class=\"medher2-section medher2-bg1\">\n    \u003Ch2 class=\"medher2-subtitle\">07 储存条件和过期处理 🧊\u003C/h2>\n    \u003Cdiv class=\"medher2-content\">\n      \u003Cul>\n        \u003Cli>\n          \u003Cstrong>曲妥珠单抗/帕妥珠单抗：\u003C/strong>应储存在2-8℃冰箱中，严禁冷冻，开启后规定时间用完，避免阳光直射。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>聚乙二醇化粒细胞刺激因子：\u003C/strong>同样2-8℃储存，取出回温后不宜复放冰箱。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>双环醇片：\u003C/strong>室温干燥避光保存即可，避免高温潮湿环境，以及儿童误取。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>过期药品：\u003C/strong>严禁继续使用，应根据当地药品废弃物规范处理，不要与生活垃圾混合。\n        \u003C/li>\n      \u003C/ul>\n      \u003Cdiv class=\"medher2-tip medher2-tip-middle\">\n        ✅ 建议：每次取用时查看药品包装及有效期，发现破损或变色不得继续使用。\n      \u003C/div>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 结尾 总结与核心提醒 -->\n  \u003Csection class=\"medher2-summary\">\n    \u003Cdiv>\n      HER2常用药在治疗中扮演着极其重要的角色，安全规范的用药流程有助于提升疗效并降低风险。请务必做到：\u003Cbr>\n      🟢 按专业要求严格执行给药方法与剂型匹配；\u003Cbr>\n      🟢 服药期间关注药品保存与使用相互作用；\u003Cbr>\n      🟢 初次或异常反应时及时与专业医护沟通、不得私自更改。\u003Cbr>\n      熟练掌握相关操作细节，就能让药品效用最大化，同时让用药更放心。\u003Cbr>\u003Cbr>\n      \u003Cstrong>安全用药——每个关键细节都不能省略。\u003C/strong>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 参考文献 -->\n  \u003Csection class=\"medher2-references\">\n    \u003Ch3 class=\"medher2-subtitle\">📚 参考文献\u003C/h3>\n    \u003Col>\n      \u003Cli>\n        Baselga, J., et al. (2012). Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. \u003Ci>The New England Journal of Medicine\u003C/i>, 366(2), 109-119.\n      \u003C/li>\n      \u003Cli>\n        Swain, S. M., et al. (2013). Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. \u003Ci>New England Journal of Medicine\u003C/i>, 372(8), 724-734.\n      \u003C/li>\n      \u003Cli>\n        Smith, T. J., et al. (2006). 2006 Update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guideline. \u003Ci>Journal of Clinical Oncology\u003C/i>, 24(19), 3187-3205.\n      \u003C/li>\n    \u003C/ol>\n  \u003C/section>\n\u003C/div>\n\n\u003Cstyle>\n.medher2-container {\n  font-family: \"Helvetica Neue\", Arial, \"PingFang SC\", \"Hiragino Sans GB\", \"Microsoft YaHei\", sans-serif;\n  max-width: 900px;\n  margin: 0 auto;\n  background: #fcfcfe;\n  color: #263238;\n  line-height: 1.85;\n  padding: 28px 28px 40px 28px;\n  border-radius: 14px;\n  box-shadow: 0 8px 32px rgba(90,120,190,0.06), 0 2px 8px rgba(0,0,0,0.01);\n}\n\n.medher2-title {\n  font-size: 2.2em;\n  letter-spacing: .02em;\n  text-align: center;\n  margin-bottom: 30px;\n  color: #205089;\n  font-weight: 700;\n  border-bottom: 2px solid #e0edfb;\n  padding-bottom: 10px;\n}\n\n.medher2-intro {\n  background: linear-gradient(to right, #e3f2fd 30%, #fafcff 100%);\n  border-radius: 10px;\n  font-size: 1.1em;\n  margin-bottom: 30px;\n  padding: 20px 28px;\n  border-left: 6px solid #48aee8;\n  color: #205089;\n}\n\n.medher2-section {\n  margin-bottom: 38px;\n  border-radius: 14px;\n  overflow: hidden;\n  padding: 0;\n  box-shadow: 0 1px 3px rgba(166,185,255,0.03);\n}\n\n.medher2-bg1 {\n  background: linear-gradient(110deg, #f7f9fc 80%, #e7ecf9 100%);\n}\n\n.medher2-bg2 {\n  background: linear-gradient(88deg, #eef8f3 40%, #e1f0e3 100%);\n}\n\n.medher2-subtitle {\n  font-size: 1.26em;\n  font-weight: 600;\n  background: rgba(60,130,246,0.11) url('data:image/svg+xml;utf8,\u003Csvg width=\"200\" height=\"40\" xmlns=\"http://www.w3.org/2000/svg\">\u003Crect width=\"200\" height=\"40\" rx=\"12\" fill=\"%23e2eefa\" />\u003C/svg>') repeat-x left center;\n  padding: 14px 28px 12px 22px;\n  margin: 0 0 10px 0;\n  border-radius: 0 0 18px 4px;\n  letter-spacing: .01em;\n  display: flex; \n  align-items: center;\n  border-left: 6px solid #9cd7df;\n}\n\n.medher2-content {\n  padding: 14px 30px 18px 32px;\n  font-size: 1.07em;\n}\n\n.medher2-content ul {\n  margin-bottom: 14px;\n  padding-left: 20px;\n}\n.medher2-content li {\n  margin-bottom: 10px;\n  line-height: 1.8;\n}\n\n.medher2-tip {\n  border-radius: 7px;\n  font-size: 1em;\n  margin: 18px 0 4px 0;\n  padding: 12px 19px;\n  line-height: 1.7;\n  background: #eaf8fd;\n  border-left: 5px solid #40b0e6;\n  color: #235188;\n}\n.medher2-tip-middle {\n  background: #f5faff;\n  border-left-color: #67c6ec;\n}\n.medher2-tip-light {\n  background: #e9f8f2;\n  border-left-color: #51bf7a;\n}\n.medher2-tip-expert {\n  background: #fdf7e8;\n  border-left-color: #d2901f;\n  color: #916d18;\n}\n\n.medher2-case {\n  border-radius: 7px;\n  margin-top: 13px;\n  padding: 11px 20px;\n  background: #e6eefb;\n  color: #254e82;\n  border-left: 5px solid #7699eb;\n  font-size: .97em;\n}\n.medher2-case-light {\n  background: #eef6fd;\n  color: #294b67;\n  border-left-color: #7fb2f2;\n}\n.medher2-case-middle {\n  background: #eeeeee;\n  border-left-color: #c4c4c4;\n}\n\n.medher2-summary {\n  font-size: 1.13em;\n  background: linear-gradient(88deg, #fff8e3 63%, #fffde7 100%);\n  border-radius: 10px;\n  margin: 35px 0 0 0;\n  padding: 18px 28px 16px 28px;\n  color: #8a5c07;\n  border-left: 6px solid #f6cf4b;\n  font-weight: 600;\n}\n\n.medher2-references {\n  margin-top: 28px;\n  font-size: 1em;\n  padding: 17px 25px 13px 35px;\n  background: #f4f7f8;\n  border-radius: 9px;\n  color: #3b4960;\n  border-left: 5px solid #67a2db;\n}\n.medher2-references h3 {\n  font-size: 1.09em;\n  font-weight: 500;\n  margin-bottom: 12px;\n  border-bottom: 1px dashed #b3cde5;\n  padding-bottom: 6px;\n}\n.medher2-references ol {\n  margin: 0;\n  padding-left: 16px;\n}\n.medher2-references li {\n  line-height: 1.5;\n  margin-bottom: 8px;\n}\n\u003C/style>\n","\u003Cdiv class=\"medher2-container\">\n  \u003Ch1 id=\"material_title\" class=\"medher2-title\">\n    🎯 HER2靶向常用药用药细",529,"2025-11-11 00:16:32","HER2靶向药, 曲妥珠单抗, 帕妥珠单抗, 乳腺癌, 用药安全, 剂量管理, 不良反应, 药物相互作用","了解HER2靶向药物（如曲妥珠单抗、帕妥珠单抗）的安全使用及管理，助您掌握关键用药细节，提升治疗效果，降低风险。","2025-12-08 06:30:00",2,[34],{"menuId":35,"menuName":36,"parentId":21,"orderNum":32,"path":37,"component":38,"isFrame":39,"isCache":40,"menuType":41,"visible":42,"status":21,"createDept":6,"remark":23,"createTime":43,"children":44,"columnImage":45,"columnLogo":46,"uncheckedLogo":6,"checkedLogo":6,"isHot":42,"isHome":21,"forceLogin":21,"color":47,"seoTitle":48,"seoKeywords":49,"seoDescription":50,"contentNum":6,"promotionalPoster":51,"menuFrame":7,"innerLink":7,"parentView":7,"routeName":52,"routerPath":37,"componentInfo":38},"1986713082609147906","健康科普","article","/article.html","1","0","T",1,"2025-11-07 16:31:25",[],"https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:49/d4291d16-ed1c-48dd-84c8-ec1f85980b75.png","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:52/6fe64094-9416-442c-a66d-032fb292666a.png","#c8e6ca","健康科普助力健康中国2030:共享健康知识新理念","健康科普, 健康中国, 科普知识, 健康家庭, 性健康, 营养健康, 运动健康, 科普宣传","探索健康科普在健康中国行动中的重要角色,了解最新的健康科普创新大赛、动漫及短视频,传播健康知识,助力全民健康。","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:56/bd33f471-6c54-4d1b-a364-b06973dbc144.png","Article","癌症肿瘤",true,{"code":9,"msg":10,"message":6,"data":56,"success":54},{"pageNo":42,"pageSize":57,"result":58,"totalSize":21},10,[],{"code":9,"msg":10,"message":6,"data":60,"success":54},{"authors":61,"appraiseDimensionScoresVos":62},[],[]]